热门搜索: 岩藻多糖   幽门螺杆菌
首页 > 科研突破
日本Tottori University大学研究:岩藻多糖可有效缓解化疗副作用
发表时间:2020-06-19         作者:岩藻多糖         来源:ONCOLOGY LETTERS 2011, 2, 319-322.        
分享至
原标题:岩藻多糖能减少不可切除及复发结肠癌患者的化疗毒性

①5-氟尿嘧啶联合亚叶酸钙与奥沙利铂化疗方案是治疗晚期结肠癌的标准疗法,大量的研究表明该方案具有很好的疗效,但是有效控制药物的毒性是延长患者寿命的重要因素;
②岩藻多糖是来自于褐藻中的含硫酸基的多糖物质,具有广泛的生物活性,尤其在缓解放化疗副作用方面效果显著;
③在本研究中,岩藻多糖被用于评价抑制抗肿瘤药物毒性的效果,20位晚期结肠癌患者被分成两组,对照组接受常规化疗方案,实验组除了常规化疗方案外,每天服用4克岩藻多糖,持续6个月;
④实验结果:岩藻多糖可以减轻化疗期间患者的疲劳感,延长化疗周期,同时可以延长患者的生存期;
⑤结论:岩藻多糖应该成为晚期结肠癌患者化疗必备的补充剂,减轻副作用,延长患者预后。

延伸阅读
ONCOLOGY LETTERS 2011, 2, 319-322.
Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer
Abstract:
Combination chemotherapy with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) or irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) has become a standard regimen for advanced or recurrent colorectal cancer. Numerous studies have reported that long-term use of FOLFOX or FOLFIRI leads to better survival for these patients. Thus, control of the toxicity of these drugs may be crucial to prolonging survival. Fucoidan is one of the major sulfated polysaccharides of brown seaweeds and exhibits a wide range of biological activities. In the present study, we analyzed the effect of fucoidan on suppressing the toxicity of anti-cancer drugs. A total of 20 patients with unresectable advanced or recurrent colorectal cancer scheduled to undergo treatment with FOLFOX or FOLFIRI were randomly allocated into a fucoidan treatment group (n=10) and a control group without fucoidan treatment (n=10). Results showed that fucoidan regulated the occurrence of fatigue during chemotherapy. Chemotherapy with fucoidan was continued for a longer period than chemotherapy without fucoidan. Additionally, the survival of patients with fucoidan treatment was longer than that of patients without fucoidan, although the difference was not signifcant. Thus, fucoidan may enable the continuous administration of chemotherapeutic drugs for patients with unresectable advanced or recurrent colorectal cancer, and as a result, the prognosis of such patients is prolonged.
First Authors:
Masahide Ikeguchi 
Correspondence:
Takayuki Kimura 
All Authors:
Masahide Ikeguchi, MANABU YAMAMOTO, Yosuke ARAI, Yoshihiko MAETA, Keigo Ashida, Kuniyuki Katano, YASUNARI Miki And Takayuki Kimura
2011-01-04 Article

新闻列表